ERBB2 and gastric cancer: This study aimed to reveal molecular and immune microenvironment characteristics of HER2‐positive GC according to response to trastuzumab‐based treatment, and to identify biomarkers that could predict trastuzumab resistance by analyzing the genetic alterations and gene expression profiles associated with worse progression‐free survival (PFS) in HER2‐positive GC.